These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Anti-Jo-1 antibody levels correlate with disease activity in idiopathic inflammatory myopathy. Stone KB; Oddis CV; Fertig N; Katsumata Y; Lucas M; Vogt M; Domsic R; Ascherman DP Arthritis Rheum; 2007 Sep; 56(9):3125-31. PubMed ID: 17763431 [TBL] [Abstract][Full Text] [Related]
9. Comparison of long-term outcome between anti-Jo1- and anti-PL7/PL12 positive patients with antisynthetase syndrome. Marie I; Josse S; Decaux O; Dominique S; Diot E; Landron C; Roblot P; Jouneau S; Hatron PY; Tiev KP; Vittecoq O; Noel D; Mouthon L; Menard JF; Jouen F Autoimmun Rev; 2012 Aug; 11(10):739-45. PubMed ID: 22326685 [TBL] [Abstract][Full Text] [Related]
10. [Jo-1-(antisynthetase-) syndrome--do autoantibodies improve classification of myositis?]. Genth E; Mierau R Z Rheumatol; 1993; 52(5):259-63. PubMed ID: 8259716 [No Abstract] [Full Text] [Related]
11. [Clinical and radiological features of adult patients with different antisynthetase syndrome based on serum anti-aminoacyl-tRNA synthetase antibody type]. Li S; Huang H; Song XY; Xu K; Wu CY; Wang Q; Xu ZJ Zhonghua Jie He He Hu Xi Za Zhi; 2017 Dec; 40(12):919-924. PubMed ID: 29224302 [No Abstract] [Full Text] [Related]
12. Serum Jo-1 Autoantibody and Isolated Arthritis in the Antisynthetase Syndrome: Review of the Literature and Report of the Experience of AENEAS Collaborative Group. Cavagna L; Nuño L; Scirè CA; Govoni M; Longo FJ; Franceschini F; Neri R; Castañeda S; Sifuentes Giraldo WA; Caporali R; Iannone F; Fusaro E; Paolazzi G; Pellerito R; Schwarting A; Saketkoo LA; Ortego-Centeno N; Quartuccio L; Bartoloni E; Specker C; Pina Murcia T; La Corte R; Furini F; Foschi V; Bachiller Corral J; Airò P; Cavazzana I; Martínez-Barrio J; Hinojosa M; Giannini M; Barsotti S; Menke J; Triantafyllias K; Vitetta R; Russo A; Bogliolo L; Bajocchi G; Bravi E; Barausse G; Bortolotti R; Selmi C; Parisi S; Salaffi F; Montecucco C; González-Gay MA; Clin Rev Allergy Immunol; 2017 Feb; 52(1):71-80. PubMed ID: 26782036 [TBL] [Abstract][Full Text] [Related]
13. The long-term outcome of anti-Jo-1-positive inflammatory myopathies. Späth M; Schröder M; Schlotter-Weigel B; Walter MC; Hautmann H; Leinsinger G; Pongratz D; Müller-Felber W J Neurol; 2004 Jul; 251(7):859-64. PubMed ID: 15258790 [TBL] [Abstract][Full Text] [Related]
14. Pseudo-perifascicular atrophy in the healing phase of Jo-1 antisynthetase syndrome. Tateyama M; Shibuya S; Sato H; Fujihara K; Aoki M Neuromuscul Disord; 2016 Aug; 26(8):521-2. PubMed ID: 27321928 [No Abstract] [Full Text] [Related]
15. Therapeutic plasma exchange in antisynthetase syndrome with severe interstitial lung disease. Omotoso BA; Ogden MI; Balogun RA J Clin Apher; 2015 Dec; 30(6):375-9. PubMed ID: 25727180 [TBL] [Abstract][Full Text] [Related]
16. Pulmonary fibrosis and myositis in a child with anti-Jo-1 antibody. Chmiel JF; Wessel HU; Targoff IN; Pachman LM J Rheumatol; 1995 Apr; 22(4):762-5. PubMed ID: 7791178 [TBL] [Abstract][Full Text] [Related]
18. Clinical heterogeneity and prognostic features of South Australian patients with anti-synthetase autoantibodies. Dugar M; Cox S; Limaye V; Blumbergs P; Roberts-Thomson PJ Intern Med J; 2011 Sep; 41(9):674-9. PubMed ID: 20059602 [TBL] [Abstract][Full Text] [Related]
20. Role of Jo-1 in the Immunopathogenesis of the Anti-synthetase Syndrome. Ascherman DP Curr Rheumatol Rep; 2015 Sep; 17(9):56. PubMed ID: 26210509 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]